Bioxytran, Inc. (OTCMKTS:BIXT) Short Interest Update

Bioxytran, Inc. (OTCMKTS:BIXT) saw a significant decrease in short interest in the month of February. As of February 28th, there was short interest totalling 6,200 shares, a decrease of 13.9% from the February 13th total of 7,200 shares. Currently, 0.0% of the shares of the company are short sold. Based on an average trading volume of 164,300 shares, the days-to-cover ratio is currently 0.0 days.

Bioxytran Stock Up 11.1 %

Shares of BIXT opened at $0.17 on Wednesday. The business has a 50-day simple moving average of $0.10 and a two-hundred day simple moving average of $0.09. The stock has a market cap of $15.33 million, a price-to-earnings ratio of -17.39 and a beta of 2.00. Bioxytran has a 52 week low of $0.06 and a 52 week high of $0.21.

Bioxytran Company Profile

Bioxytran, Inc, a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company’s lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing.